Constipation — having bowel movements less often than usual or stools that are hard or difficult to pass — can affect how you feel throughout your day, disrupt routines, and make other multiple ...

Foralumab stabilized disability for 6 months in all 10 people with nonactive SPMS who took part in an expanded access program, a study found.

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.

The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the brains of people with progressive forms of multiple sclerosis, according to new ...

PRESS RELEASEAB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL ...

Multiple sclerosis (MS) is best known for the physical symptoms it can cause, such as numbness, weakness, spasticity, and difficulty walking. But this autoimmune disease of the central nervous system ...

Up to 85% of the people who receive a diagnosis of the neurodegenerative disorder multiple sclerosis (MS) have the relapsing-remitting (RR) disease course. This means that people have relapses -- also ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

Multiple sclerosis (MS) is an inflammatory condition that damages the myelin of the central nervous system, leading to neurologic impairment and possibly severe disability. MS is characterized by ...

Multiple sclerosis (MS) is a disorder that prompts the body's immune system to attack myelin, the protective sheath covering nerve cells in the brain, optic nerve and spinal cord. This can in turn ...

Scientists have identified an unusual type of brain cell that may play a vital role in progressive multiple sclerosis (MS), likely contributing to the persistent inflammation characteristic of the ...

Three investigators and their teams have received funding for clinical trial development projects as part of the International Progressive MS Alliance’s Experimental Medicine Trial Awards. These ...